- Home
- SJT vs SCPH Comparison
SJT vs SCPH Comparison
Compare SJT & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- SCPH
- Stock Information
- Founded
- SJT 1980
- SCPH 2013
- Country
- SJT United States
- SCPH United States
- Employees
- SJT N/A
- SCPH N/A
- Industry
- SJT Oil & Gas Production
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- SJT Energy
- SCPH Health Care
- Exchange
- SJT Nasdaq
- SCPH Nasdaq
- Market Cap
- SJT 181.8M
- SCPH 179.6M
- IPO Year
- SJT N/A
- SCPH 2017
- Fundamental
- Price
- SJT $4.49
- SCPH $3.51
- Analyst Decision
- SJT
- SCPH Strong Buy
- Analyst Count
- SJT 0
- SCPH 2
- Target Price
- SJT N/A
- SCPH $15.00
- AVG Volume (30 Days)
- SJT 286.8K
- SCPH 448.7K
- Earning Date
- SJT 11-14-2024
- SCPH 11-13-2024
- Dividend Yield
- SJT 2.48%
- SCPH N/A
- EPS Growth
- SJT N/A
- SCPH N/A
- EPS
- SJT 0.19
- SCPH N/A
- Revenue
- SJT $11,031,594.00
- SCPH $30,278,000.00
- Revenue This Year
- SJT N/A
- SCPH $172.64
- Revenue Next Year
- SJT N/A
- SCPH $131.43
- P/E Ratio
- SJT $22.59
- SCPH N/A
- Revenue Growth
- SJT N/A
- SCPH 303.87
- 52 Week Low
- SJT $3.21
- SCPH $3.08
- 52 Week High
- SJT $5.81
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- SJT 64.95
- SCPH 50.42
- Support Level
- SJT $4.07
- SCPH $3.27
- Resistance Level
- SJT $4.28
- SCPH $3.58
- Average True Range (ATR)
- SJT 0.21
- SCPH 0.18
- MACD
- SJT 0.06
- SCPH 0.02
- Stochastic Oscillator
- SJT 98.81
- SCPH 52.94
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.